The objectives of this core are to isolate and propagate primary human leukocytes (monocytes and peripheral blood lymphocytes and maintain a brain bank of pathological tissues [for all projects and cores]. In addition, the core will provide murine bone-marrow-derived macrophages, human and murine neuronal and glial cells for studies of neural progenitors and cell-based nanoformulations in neuroAIDS. Rigorous quality control measures are in place for this well-integrated core. Substantive uses of these facilities were provided to all investigators during the previous funding cycle. Primary human leukocytes will be fractionated into monocytes and lymphocytes from HIV-1, 2 and hepatitis B and C seronegative donors by centrifugal elutriation. Human glia (microglia and astrbcytes) and/or neurons will be obtained from fetal tissues. The neurons, glia, and/or progenitor cells from human and mouse brain tissue will be purified, characterized and provided for experiments (all projects). The Brain Bank will also be operated through this core. Two hundred and thirty-six specimens are available, which include tissues with neuropathological diagnoses of Alzheimer's disease, HIV-1-associated dementia and other neurodegenerative disorders (including but not limited to stroke, Parkinson's disease, and multiple sclerosis). Patients who died of diseases not related to the nervous system serve as age-matched controls. These primary adult human cells and other tissues from Brain Bank will be utilized within to prepare RNA and protein specimen banks. Brain tissue lysates for RNA and protein investigations and frozen and paraffin tissues for immunohistochemistry will be an available resource. These will provide data for common endpoints of disease. In toto, this 'cells and tissue core'will provide all the biological specimens necessary to address research objectives of the program project and utilize the carefully controlled specimens obtained through this infrastructure to investigate neural immunity and its links to neurodegeneration.
| Olson, Katherine E; Bade, Aditya N; Namminga, Krista L et al. (2018) Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. J Neurovirol 24:398-410 |
| Schutt, Charles R; Gendelman, Howard E; Mosley, R Lee (2018) Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Mol Neurodegener 13:26 |
| Thomas, Midhun B; Gnanadhas, Divya Prakash; Dash, Prasanta K et al. (2018) Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine (Lond) 13:2139-2154 |
| Kiyota, Tomomi; Machhi, Jatin; Lu, Yaman et al. (2018) URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease. J Neuroinflammation 15:137 |
| Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276 |
| McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62: |
| Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40 |
| Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65 |
| Kevadiya, Bhavesh D; Ottemann, Brendan M; Thomas, Midhun Ben et al. (2018) Neurotheranostics as personalized medicines. Adv Drug Deliv Rev : |
| Zhou, Tian; Lin, Zhiyi; Puligujja, Pavan et al. (2018) Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine (Lond) 13:871-885 |
Showing the most recent 10 out of 240 publications
